首页> 美国卫生研究院文献>other >Angiotensin converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4 deficient mice
【2h】

Angiotensin converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4 deficient mice

机译:血管紧张素-4缺乏症小鼠升主动脉瘤需要血管紧张素转换酶诱导的局部血管紧张素信号激活

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aortic aneurysms are life-threatening and often associated with defects in connective tissues and mutations in smooth muscle cell (SMC) contractile proteins. Despite recent advances in understanding altered signaling in aneurysms of Marfan syndrome, the underlying mechanisms and options for pharmacological treatment for other forms of aneurysms are still under investigation. We previously showed in mice that deficiency in the fibulin-4 gene in vascular SMCs (Fbln4SMKO) leads to loss of the SMC contractile phenotype, hyperproliferation and ascending aortic aneurysms. Here, we report that abnormal upregulation of angiotensin converting enzyme (ACE) in SMCs and subsequent activation of angiotensin II (AngII) signaling is involved in the onset of aortic aneurysms in Fbln4SMKO mice. In this model, aneurysm formation was completely prevented by inhibition of the AngII pathway with losartan or captopril within a narrow therapeutic window during the first month of life, even though the altered mechanical properties of blood vessel walls were not reversed by the pharmacological treatment. The therapeutic effects of losartan in Fbln4SMKO mice do not require the AngII receptor type 2 (Agtr2) but likely require both type 1a (Agtr1a) and 1b (Agtr1b) receptors. The results indicate that fibulin-4 is a vascular matrix component required for regulation of local angiotensin signaling, aortic aneurysms, and development and maintenance of the SMC phenotype.
机译:主动脉瘤威胁生命,通常与结缔组织缺陷和平滑肌细胞(SMC)收缩蛋白突变有关。尽管最近在理解马凡氏综合征的动脉瘤信号改变方面有了新进展,但仍在研究其他形式的动脉瘤的药物治疗的基本机制和选择。我们先前在小鼠中发现血管SMCs的fibulin-4基因缺乏(Fbln4 SMKO )会导致SMC收缩表型丧失,过度增殖和升主动脉瘤。在这里,我们报道,SMC中血管紧张素转换酶(ACE)的异常上调和随后血管紧张素II(AngII)信号的激活与Fbln4 SMKO 小鼠主动脉瘤的发作有关。在该模型中,即使在药理学治疗并未逆转血管壁机械特性改变的情况下,通过在生命的狭窄月窗内通过氯沙坦或卡托普利抑制AngII途径来完全防止动脉瘤的形成。氯沙坦对Fbln4 SMKO 小鼠的治疗作用不需要AngII 2型受体(Agtr2),但可能同时需要1a(Agtr1a)和1b(Agtr1b)受体。结果表明,fibulin-4是调节局部血管紧张素信号传导,主动脉瘤以及SMC表型发育和维持所需的血管基质成分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号